Omeprazole extended release - Depomed

Drug Profile

Omeprazole extended release - Depomed

Alternative Names: DM-3458

Latest Information Update: 28 Apr 2011

Price : $50

At a glance

  • Originator Depomed
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Aug 2006 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)
  • 02 May 2005 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top